ROCKVILLE, Md., March 25 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: ENMD) a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced that James S. Burns, President and Chief Executive Officer, will present a Corporate overview at the BioCentury Future Leaders in the Biotech Industry Conference, to be held at the Millennium Broadway Hotel & Conference Center, March 27, 2008. Mr. Burns' presentation is scheduled for Thursday, March 27, 2008 at 4:00 p.m. (local time).
Mr. Burns' live presentation will be web cast and can be accessed through the Company's web site at http://www.entremed.com. An archive will be available on the web site for approximately 90 days.
EntreMed, Inc. is a clinical-stage pharmaceutical company developing
therapeutic candidates primarily for the treatment of cancer and
inflammation. MKC-1 is currently in multiple Phase 2 clinical trials for
cancer. MKC-1 is an oral cell-cycle regulator with activity against the
mTOR pathway. ENMD-1198, a novel antimitotic agent, is in a Phase 1 study
in advanced cancer patients, and ENMD-2076, a selective kinase inhibitor,
is expected to begin a Phase 1 study in 2Q08. The Company also has an
approved IND application for Panzem(R) in rheumatoid arthritis. EntreMed's
goal is to develop and commercialize new compounds based on the Company's
expertise in angiogenesis, cell-cycle regulation and inflammation --
processes vital to the treatment of cancer and other diseases, such as
rheumatoid arthritis. Additional information about EntreMed is available on
the Company's web site at http://www.entremed.com and in various filings with the
Securities and Exchange Commission.
Corporate Communications & Investor Relations
|SOURCE EntreMed, Inc.|
Copyright©2008 PR Newswire.
All rights reserved